Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.…
Fresenius Medical Care AG (FMS) (Q3 2026) Earnings Call Highlights: Stable Revenue, 5008X ...
Fresenius Medical Care (NYSE: FMS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 106,291 employees.
The shares were at 20.44 USD on 20 November 2026, down 6.7% over 52 weeks. Its 52-week range is 20.00 USD to 26.42 USD: the price is 22.6% below the high and 2.2% above the low.
At a market capitalisation of 10.61B USD, it trades at 11.8 times trailing earnings and 7.8 times forward earnings. The median trailing P/E of its 17 largest Medical Care Facilities peers is 24.8, a discount of 52% for FMS. It pays a dividend yielding 4.33% (it pays out 50% of its earnings), against a median of 0.66% among the dividend payers in that peer group.
Fresenius Medical Care reports return on equity of 7.4%, an operating margin of 10.1% and revenue up 1.1% year over year.
Its debt exceeds its cash by 9.80B EUR, a debt-to-equity ratio of 0.81. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 21.56 USD is 5.5% above the current price. The next earnings report is expected on 23 February 2027.